United Drug has reported adjusted pre-tax profits of €38m for the six months to the end of March, an increase of 8% on the same time the previous year.
The international healthcare provider said that half yearly revenues rose by 14% to €1.02 billion, while operating profits rose by 13% to €44.6m.
United Drug's board has declared an interim dividend of 2.61 cent per share, up 5% on the 2012 interim dividend.
During the six month period, the company said that the US has become its largest profit contributing region, followed closely by the UK and the rest of Europe.
In its results statement today, the company said that it plans to rebrand the group as ''UDG Healthcare'' in September subject to shareholder approval.
''The first half of 2013 has seen us integrate our recent acquisitions, structure our business for future growth and deliver operating profit growth,'' commented the company's chief executive Liam FitzGerald.
''We continue to work hard to provide a range and quality of professional outsourcing solutions that enable our international healthcare clients to operate more effectively,'' he added.
See how United Drug shares performed in Dublin today
United Drug said that revenues at its sales, marketing and medical division jumped by 113% to €118m after the purchase of the Pharmexx businesses. Operating profits for the six month rose by 29%.
Revenue in its healthcare supply chain, which operates in Ireland, the UK and the Netherlands, inched 1% higher to €736m while operating profits grew by 2%. United Drug said that underlying volume growth in Ireland and market share gains have helped to offset on-going regulatory pressure.
Its packaging and speciality division reported a 26% rise in revenues to €99m while operating profits increased by 25%. United Drug said it has invested heavily in its Irish speciality homecare business after winning a Government tender to provide infusion services in patients' homes.
